Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Cemiplimab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Cemiplimab | Phase III | Actionable | In a Phase III trial (EMPOWER-Lung 3), first-line Libtayo (cemiplimab) and platinum-doublet chemotherapy combination treatment (n=217) significantly improved median overall survival (23.5 vs 12.1 mo, HR=0.51, p<0.0001) and median progression-free survival (8.3 vs 5.5 mo, HR=0.48, p<0.0001) compared to chemotherapy and placebo (n=110) in patients with advanced non-small cell lung cancer with CD274 (PD-L1) expression >/= 1% and without EGFR, ALK, or ROS1 aberrations (PMID: 38820979; NCT03409614). | 38820979 |
PubMed Id | Reference Title | Details |
---|---|---|
(38820979) | Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. | Full reference... |